Losartan as the Preferred ARB for Thoracic Aortic Aneurysm Management

Guideline Recommendations

The 2010 ACC/AHA guideline (Class IIa, Level B) states that losartan is a reasonable pharmacologic option for individuals with Marfan‑related thoracic aortic aneurysm to reduce the rate of aortic dilatation. 1
The 2022 ACC/AHA guideline recommends either a beta‑blocker or an ARB at maximally tolerated doses for thoracic aortic aneurysm, highlighting losartan as the ARB with the strongest supporting evidence. 2
The 2024 Mayo Clinic guideline identifies losartan as the only ARB with demonstrated efficacy through transforming growth factor‑β inhibition in thoracic aortic aneurysm patients. 3, 4, 5, 6

Pre‑clinical studies showed that losartan prevented aneurysm formation in mouse models of Marfan syndrome and markedly slowed aortic root growth in early human investigations. 1, 2
Randomized controlled trials demonstrated that losartan achieved aortic root growth reduction comparable to that of beta‑blockers. 2

Initiate losartan and titrate to the highest dose tolerated (commonly 50–100 mg daily) to achieve adequate blood‑pressure control. 2
Adding losartan to a beta‑blocker is a Class IIa recommendation when aortic dilation persists on monotherapy. 2
Combination therapy (beta‑blocker + losartan) produced greater reductions in aortic root growth over 3–5 years compared with either agent alone. 2
A meta‑analysis of combination therapy reported an approximate 50 % reduction in the annual aortic growth rate. 3, 4, 5, 6

Surgical repair is indicated when the aortic root diameter reaches ≥ 5.0 cm (Class I recommendation). 2
In the presence of additional risk factors (e.g., family history of dissection, rapid growth > 0.5 cm/year, or desire for pregnancy), surgery may be considered at a diameter of ≥ 4.5 cm. 2

Losartan is the only ARB that has been specifically studied and incorporated into major guidelines for thoracic aortic aneurysm management. 1, 2
Valsartan was associated with a lower incidence of aortic dissection in the Jikei Heart Study, but this observation was a secondary finding in a general hypertensive cohort and not specific to aneurysm treatment. 1

Beta blockers have long been the foundation of medical therapy for Marfan syndrome to reduce heart rate, myocardial contractility, and slow aortic root growth 7, 8
Beta blockers are recommended in maximally tolerated doses unless contraindicated 9
Angiotensin Receptor Blockers (ARBs), particularly losartan, have been shown to be as effective as beta blockers in reducing aortic dilation rates 7, 10
Losartan was initially shown to prevent aneurysm formation in models of Marfan syndrome 7
In a small, non-randomized open-label study of children with Marfan syndrome, ARBs dramatically slowed aortic root growth 7

The combination of a beta blocker and an ARB in maximally tolerated doses is reasonable to reduce the rate of aortic dilation (Class 2a recommendation) 7, 10
Multiple trials have shown that adding an ARB to beta blocker therapy led to a reduction in aortic root growth rates over 3-5 years of follow-up 7
A meta-analysis confirmed slower aortic growth rates with combination therapy compared to monotherapy 7

Initial therapy: Start with either a beta blocker (e.g., propranolol, atenolol) titrated to maximally tolerated dose or an ARB (e.g., losartan) titrated to maximally tolerated dose 7
Optimization: If single agent is well-tolerated but aortic dilation continues, consider combination therapy with both a beta blocker and ARB 7, 10
Monitoring: Regular imaging of the aortic root with echocardiography, CT, or MRI to assess treatment efficacy 11

Despite medical therapy, surgical intervention is still recommended when aortic root diameter reaches ≥5.0 cm (Class 1 recommendation) 7, 8
Surgery may be reasonable at smaller diameters (≥4.5 cm) in patients with risk factors for aortic dissection 7
The primary goal of medical therapy is to slow the rate of aortic dilation, not to reverse existing dilation 7

For children with Marfan syndrome, beta blocker treatment has been associated with reduced aortic growth rate (slowed by approximately 0.2 mm/year) 12
Regular monitoring of blood pressure is essential to ensure adequate dosing of antihypertensive medications 9